Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Naval Group signs contract for four defence and intervention frigates (FDI) for the Royal Swedish Navy

 Vinge has advised Naval Group in connection with the negotiations with the Swedish Defence Materiel Administration (FMV) for the procurement of four defence and intervention frigates (FDI) for the Swedish Navy. The contract was signed on 31 August 2026 in Stockholm. Naval Group has been selected as a strategic partner by the Swedish Government to rapidly strengthen and modernise its fleet's capabilities.
September 08, 2026

Vinge advises Axcel and Sanviva on the acquisitions of DermaCura and YourRad

 Vinge has advised Axcel Elevate I and Sanviva in connection with the acquisitions of DermaCura and YourRad.
September 07, 2026

Vinge advises Revivo Group on the acquisition of Premator

 Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026